The Beauty Health Company — Q3 2023 Form 10-Q Summary
Filing identification: The provided filing is for The Beauty Health Company (Nasdaq: SKIN), not “Skinhealth Systems Inc.” It covers the three and nine months ended September 30, 2023. The company designs, manufactures, markets, and sells esthetic technologies and related consumables, including Hydrafacial, SkinStylus, and Keravive.
Business Context and Reporting Period
The company operates as one reportable segment. Revenue is generated primarily from Hydrafacial Delivery Systems and recurring consumables, including serums, solutions, tips, and related products. The filing states that prior-period financial statements were revised for immaterial misstatements involving intercompany balances and right-of-return assets.
Key Financial Metrics
| Metric | Q3 2023 | Q3 2022 | Change |
|---|---|---|---|
| Net sales | $97.4 million | $88.8 million | 9.7% increase |
| Gross profit (loss) | $(12.6) million | $61.4 million | Declined $73.9 million |
| Gross margin | (12.9%) | 69.1% | Down 82.0 percentage points |
| Operating loss | $(82.1) million | $(4.4) million | Loss increased $77.7 million |
| Net loss | $(73.8) million | $(0.1) million | Material deterioration |
| Basic loss per share | $(0.56) | $0.00 | — |
| Metric | Nine months 2023 | Nine months 2022 | Change |
|---|---|---|---|
| Net sales | $301.2 million | $267.7 million | 12.5% increase |
| Gross profit | $109.4 million | $182.3 million | 40.0% decrease |
| Gross margin | 36.3% | 68.1% | Down 31.8 percentage points |
| Operating loss | $(112.6) million | $(23.4) million | Loss increased $89.2 million |
| Net income (loss) | $(90.7) million | $37.7 million | Declined $128.4 million |
| Basic earnings (loss) per share | $(0.68) | $0.25 | — |
Revenue Mix
- Q3 Delivery Systems revenue was $51.0 million, up 4.0% year over year.
- Q3 Consumables revenue was $46.4 million, up 16.8% year over year.
- Nine-month Delivery Systems revenue was $162.0 million, up 4.2%.
- Nine-month Consumables revenue was $139.2 million, up 24.0%.
- Q3 geographic revenue was $51.7 million in the Americas, $24.7 million in Asia-Pacific, and $21.1 million in EMEA.
Cash Flow, Liquidity, and Debt
- Cash and cash equivalents were $559.4 million at September 30, 2023, compared with $568.2 million at December 31, 2022.
- Nine-month operating cash flow was positive $26.9 million, compared with negative $101.2 million in the prior-year period.
- Nine-month investing cash flow was negative $29.3 million, including $18.5 million for asset acquisitions and $3.8 million for property and equipment.
- Nine-month financing cash flow was negative $6.1 million, compared with negative $102.8 million in the prior-year period, primarily because the prior year included significant accelerated share repurchases.
- The company had $750.0 million principal amount of 1.25% convertible senior notes due 2026, reported at a net carrying value of $737.3 million.
- A $50.0 million revolving credit facility due 2027 was undrawn at September 30, 2023. The company reported compliance with its debt covenants.
- Management stated that available liquidity is sufficient for anticipated working capital requirements and operations for at least the next twelve months, including the Syndeo remediation program.
Material Changes Versus the Prior Comparable Period
- Revenue increased, led particularly by consumables and international sales, but profitability deteriorated sharply.
- Q3 cost of sales increased to $110.0 million from $27.4 million, primarily because of $63.1 million of Syndeo-related inventory write-downs and program charges, $7.5 million of other discontinued, excess, or obsolete inventory charges, higher product costs, and lower average selling prices for Delivery Systems.
- Selling and marketing expense declined 22.7% in Q3, while general and administrative expense increased 55.5%, driven primarily by personnel costs, severance, share-based compensation, software, and professional fees.
- Nine-month interest income increased to $16.8 million from $3.6 million due primarily to higher returns on money market funds.
- The prior-year period included a $71.5 million gain from the change in fair value of warrant liabilities; the comparable 2023 gain was $8.4 million, reducing the favorable non-operating impact.
- Inventory declined to $74.9 million from $109.7 million at year-end 2022, partly because of write-downs.
- Total stockholders’ equity declined to $90.0 million from $167.1 million, primarily reflecting the nine-month net loss.
Guidance, Outlook, Risks, and Unusual Items
Syndeo Program
The company reported persistent performance issues with Syndeo 1.0 and 2.0 devices, including low flow, clogs, treatment interruptions, and difficult maintenance. Syndeo 3.0 incorporates hardware and software enhancements intended to improve reliability. The company will market and sell Syndeo 3.0 exclusively and will offer customers either field upgrades or replacement devices at no cost, together with a one-year warranty extension.
- Q3 Syndeo program charges were $44.3 million, with $12.3 million used during the quarter.
- The company recorded an $18.8 million write-down for obsolete Syndeo 1.0 and 2.0 inventory.
- The accrued Syndeo reserve was $32.1 million at September 30, 2023.
- Remediation is expected to be substantially completed by June 30, 2024.
- Management estimates that most customers will request replacement Syndeo 3.0 devices. The reserve is sensitive to customer elections and remediation costs.
Business Transformation Program
- Phase 1 is expected to be substantially completed by March 31, 2024 and is expected to cost $9 million to $11 million.
- The company recorded $0.6 million of Phase 1 restructuring charges in Q3.
- Management expects Phase 1 to generate more than $20 million of annualized savings exiting Q1 2024.
- Phase 2 is expected to focus on manufacturing optimization, but its total cost and savings have not been finalized. Management expects more than $15 million of annualized savings exiting Q2 2024.
Other Unusual Items and Risks
- The company received $5.4 million under the Employee Retention Credit, with $4.9 million recorded in other income and $0.5 million in interest income.
- The board authorized a $100 million share repurchase program. Approximately $4.8 million was spent in Q3 for roughly 0.8 million shares; the company stated it expects to repurchase $50 million by the end of Q1 2024, including Q3 purchases.
- Material risks include continued Syndeo product failures, customer acceptance of Syndeo 3.0, product recalls or remediation costs, macroeconomic weakness, inflation, higher interest rates, foreign exchange volatility, supply-chain disruptions, competitive pressures, litigation, and the company’s substantial convertible-note obligations.
- Pending legal matters include patent litigation involving Cartessa and proceedings related to Ageless. The Ageless settlement provides for total payments of $1.4 million to Hydrafacial over time, subject to the confirmed bankruptcy plan.
- The company maintains cash balances that may exceed FDIC insurance limits, creating potential bank-counterparty risk.
Most Important Facts for Investors to Verify
- Whether Syndeo 3.0 materially improves customer satisfaction, return rates, device reliability, and future Delivery Systems demand.
- Whether the $32.1 million Syndeo reserve is sufficient, particularly given the expected preference for device replacements and the disclosed sensitivity to customer elections and remediation costs.
- Whether the business transformation program achieves its projected cost savings and whether Phase 2 costs can be quantified.
- Whether gross margins recover after Syndeo-related charges and other inventory obsolescence costs subside.
- The company’s ability to service or refinance the $750 million convertible notes due 2026 while maintaining sufficient liquidity.
- The effect of share repurchases, equity compensation, convertible notes, and warrants on future share count and dilution.
- The status and potential financial impact of the Cartessa litigation and the remaining Ageless settlement obligations.
- The accuracy of the company’s liquidity assessment, including cash needs for Syndeo remediation, restructuring, acquisitions, and ongoing operations.